单位：[1]Department of Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.医技科室北京市临床医学研究所国家消化中心（方法学平台）首都医科大学附属北京友谊医院[2]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.临床科室国家中心肝病分中心首都医科大学附属北京友谊医院
Background: High uptake of hepatitis B virus (HBV) tests and antiviral therapy are required to improve the clinical outcomes of patients with chronic hepatitis B (CHB) at the population level. In the current study, we used the Basic Medical Care Insurance for Employees (BMCIE) to investigate the changes of clinical care cascade of CHB in Beijing, China. Methods: Records for medical service of CHB patients from January 1, 2010 to December 31, 2018 were retrieved from the BMCIE database. The annual and cumulative rates of CHB patients in care, receiving HBV tests and on antiviral therapy were calculated. The trends of annual percentage changes (APCs) were estimated using Joinpoint regression model. Findings: Among estimated HBsAg positive employees, the rate of CHB patients in care increased from 4.77% in 2010 to 18.61% in 2018 (APC-17.3, 95%CI: 14.4-20.4). The rate of HBV tests increased from 4.41% in 2010 to 16.39% in 2018. Among the estimated eligible employees for treatment, the rate of antiviral therapy increased from 3.92% in 2010 to 30.88% in 2018. The proportion of hospital visits for HBV >= 4 times per year had increased from 47.07% in 2010 to 65.31% in 2018. By 2018, entecavir (65.07%) and tenofovir (12.98%) had become the predominantly prescribed antiviral agents. Interpretation: The rates of CHB patients in care, receiving HBV tests and on antiviral therapy substantially increased in Beijing, China. However, more efforts are still needed to increase the uptake of HBV tests and treatment for achieving the goal of HBV elimination by 2030. (C) 2021 The Author(s). Published by Elsevier Ltd.
基金：
Beijing Municipal Science and Technology CommissionBeijing Municipal Science & Technology Commission [D161100002716003]; National Science and Technology Major Special Project for Infectious Diseases [2018ZX10302204, Z191100007619037]; Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals [XXX 0104]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
无
最新[2025]版：
大类|1 区医学
小类|1 区卫生保健与服务1 区公共卫生、环境卫生与职业卫生
JCR分区：
出版当年[2019]版：
无
最新[2023]版：
Q1HEALTH CARE SCIENCES & SERVICESQ1PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
第一作者单位：[1]Department of Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
通讯作者：
通讯机构：[1]Department of Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.[2]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.[*1]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong-an Road, Beijing 10 0 050, China[*2]Department of Clinical Epidemiol-ogy and EBM Unit, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong-an Road, Beijing 10 0 050, China
推荐引用方式(GB/T 7714)：
Li Min,Zhao Lianhui,Zhou Jialing,et al.Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China[J].LANCET REGIONAL HEALTH-WESTERN PACIFIC.2021,16:doi:10.1016/j.lanwpc.2021.100249.
APA：
Li Min,Zhao Lianhui,Zhou Jialing,Sun Yameng,Wu Xiaoning...&Jia Jidong.(2021).Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China.LANCET REGIONAL HEALTH-WESTERN PACIFIC,16,
MLA：
Li Min,et al."Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China".LANCET REGIONAL HEALTH-WESTERN PACIFIC 16.(2021)
医学